相关临床试验
5
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
20.0%
已完成
4
80.0%
暂无批准数据
- A new artificial intelligence model, PROGRxN-BCa, trained on over 12,000 patients, outperforms current guideline-endorsed risk calculators for non-muscle invasive bladder cancer progression by approximately 10%. - The model effectively sub-stratifies the heterogeneous intermediate-risk NMIBC patient group into distinct risk tertiles, enabling more personalized treatment approaches based on progression probability. - Developed using 14 readily available clinicopathological features, PROGRxN-BCa requires no specialized biomarkers or histopathological slides, making it practical for routine clinical implementation.
- A pioneering European trial in Ireland combines PSA blood tests, risk factor analysis, and MRI scans to improve prostate cancer screening accuracy in men aged 50-60. - The PRAISE-U study aims to reduce unnecessary biopsies while detecting cancer earlier, potentially decreasing mortality rates by 40% through targeted screening approaches. - Currently, around 12,000 men annually in the UK are diagnosed too late for curative treatment, highlighting the urgent need for improved early detection methods.
